Angle
Medical diagnostics company with products in the cancer diagnostics and fetal health markets.
Launch date
Employees
Market cap
$47.9m
Enterprise valuation
$32m (Public information from Sep 2024)
Share price
£0.10978 AGL.L
Company register number 10087031
Guildford England (HQ)
Financials
Estimates*
GBP | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | <1m | 1.0m | 1.0m | 2.2m | 8.3m | 17.2m | 36.1m |
% growth | - | 33 % | 3 % | 110 % | 277 % | 108 % | 110 % |
EBITDA | (12.2m) | (15.7m) | (21.2m) | (18.9m) | (14.8m) | (12.5m) | (3.1m) |
% EBITDA margin | (1606 %) | (1552 %) | (2040 %) | (865 %) | (179 %) | (73 %) | (9 %) |
Profit | (11.6m) | (15.0m) | (21.7m) | (20.1m) | (15.8m) | (13.8m) | (5.8m) |
% profit margin | (1523 %) | (1482 %) | (2083 %) | (921 %) | (192 %) | (81 %) | (16 %) |
EV / revenue | 97.3x | 244.6x | 95.7x | 6.6x | 5.3x | 2.5x | 1.2x |
EV / EBITDA | -6.1x | -15.8x | -4.7x | -0.8x | -3.0x | -3.4x | -14.1x |
R&D budget | 3.7m | 3.4m | 4.5m | 2.5m | - | - | - |
R&D % of revenue | 480 % | 340 % | 431 % | 113 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $250k | Early VC | |
N/A | N/A | IPO | |
N/A | £20.0m | Post IPO Equity | |
* | N/A | £20.1m | Post IPO Equity |
* | N/A | £500k | Post IPO Equity |
Total Funding | $250k |
Recent News about Angle
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.